8XB.SG - Biocartis Group NV

Stuttgart - Stuttgart Delayed Price. Currency in EUR
0.5460
+0.0040 (+0.74%)
At close: 03:29PM CEST
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.5420
Open0.5460
Bid0.5450 x 25000
Ask0.5930 x 32200
Day's Range0.5450 - 0.5460
52 Week Range0.4945 - 2.1000
Volume0
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 8XB.SG

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Press release Biocartis Group NV: Results of the Annual Shareholders’ Meeting held on 12 May 2023

      PRESS RELEASE: REGULATED INFORMATION12 May 2023, 17:40 CEST Results of the Annual Shareholders’ Meeting held on 12 May 2023 Mechelen, Belgium, 12 May 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), held its annual shareholders' meeting today at its offices in Mechelen, Belgium. The shareholders approved all items on the agenda, with the exception of the agenda item regarding the approval of certain features of the

    • GlobeNewswire

      Press release Biocartis Group NV: Biocartis and HiloProbe to Collaborate on Colorectal Cancer Test

      PRESS RELEASE: 9 May 2023, 07:00 CEST Biocartis and HiloProbe to Collaborate on Colorectal Cancer Test Mechelen, Belgium, 9 May 2023 - Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), and HiloProbe, a Umeå (Sweden) based biotechnology company focused on personalizing colorectal cancer diagnostics, today announce that they entered into a collaboration that will initially focus on the commercialization of ColoNode®, a CE-mar

    • GlobeNewswire

      Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities

      PRESS RELEASE: REGULATED INFORMATION28 April 2023, 17:40 CEST Disclosure of Outstanding Voting Securities Mechelen, Belgium, 28 April 2023 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that in the course of April 2023 a further portion of receivables due by the Company to Highbridge under the senior secured 'Facility Agreement' (as amended from time to time) ("First Lien Loan Agreement") concluded with

    • GlobeNewswire

      Press release Biocartis Group NV: Biocartis Reports Results of First Quarter of 2023

      PRESS RELEASE: REGULATED INFORMATION20 April 2023, 07:00 CEST Biocartis Reports Results of First Quarter of 2023:16% Growth of Oncology Cartridge RevenuesGross Margin on Products of 37% and EBITDA of EUR -8.4m Mechelen, Belgium, 20 April 2023 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), today provides a business update for the first quarter of 2023 and the outlook for the full year 2023. Commenting on the Q1 2023 res

    • GlobeNewswire

      Press release Biocartis Group NV: Biocartis appoints Roger Moody as new CEO

      PRESS RELEASE: INSIDE INFORMATION/ REGULATED INFORMATION11 April 2023, 22:00 CEST Biocartis appoints Roger Moody as new CEO Roger Moody to be appointed as new Chief Executive Officer and member of the Board of DirectorsHerman Verrelst, current Chief Executive Officer, will move into the position of Executive Chairman of the Board of DirectorsAdditional extensive experience in the US diagnostic market while leveraging existing knowledge and relationships Mechelen, Belgium, 11 April 2023 - Biocart

    • GlobeNewswire

      Press release Biocartis Group NV: Invitation to the Annual Shareholders’ Meeting

      PRESS RELEASE: REGULATED INFORMATION 11 April 2023, 07:01 CEST Invitation to the Annual Shareholders’ Meeting Mechelen, Belgium, 11 April 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), has the honor to invite its shareholders, holders of subscription rights, holders of convertible bonds, directors and statutory auditor to its annual shareholders' meeting (‘AGM’) that will be held on Friday 12 May 2023 at 2:00 p.m.

    • GlobeNewswire

      Press release Biocartis Group NV: Biocartis Announces Publication of 2022 Annual Report

      PRESS RELEASE: REGULATED INFORMATION 11 April 2023, 07:00 CEST Biocartis Announces Publication of 2022 Annual Report Mechelen, Belgium, 11 April 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the publication of its 2022 annual report. The 2022 annual report among others includes the consolidated financial statements and performance of Biocartis for the financial year ended on 31 December 2022. The

    • GlobeNewswire

      Press release Biocartis Group NV: Biocartis and APIS Assay Technologies Sign Collaboration to Develop and Commercialise a Breast Cancer Subtyping Test on the Idylla™ platform

      PRESS RELEASE: 4 April 2023, 07:00 CEST Biocartis and APIS Assay Technologies Sign Collaboration to Develop and Commercialise a Breast Cancer Subtyping Test on the Idylla™ platform Mechelen, Belgium, 4 April 2023 - Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), and APIS Assay Technologies Ltd., a private UK based company specializing in molecular diagnostics, today announce that they have entered into a new partnership a

    • GlobeNewswire

      Press release Biocartis Group NV: Biocartis To Publish 2022 Annual Report on 11 April 2023

      PRESS RELEASE - REGULATED INFORMATION 29 March 2023, 07:00 CEST Biocartis To Publish 2022 Annual Report on 11 April 2023 Mechelen, Belgium, 29 March 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it will publish its 2022 annual report on 11 April 2023, which is later than the previously communicated publication date, because the audit of the consolidated financial statements is not finalized w

    • GlobeNewswire

      Press release Biocartis Group NV: Disclosure of transparency notification

      PRESS RELEASE - REGULATED INFORMATION 3 March 2023, 17:40 CET Disclosure of transparency notification Mechelen, Belgium, 3 March 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down miscellaneous prov

    • GlobeNewswire

      Press release Biocartis Group NV: Biocartis announces the US FDA 510(k) clearance for the Idylla™ MSI Test

      PRESS RELEASE 2 March 2023, 7:00 CET BIOCARTIS ANNOUNCES THE US FDA 510(k) CLEARANCE FOR THE IDYLLA™ MSI TEST Mechelen, Belgium, 2 March 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the U.S. Food and Drug Administration (FDA) 510(k) clearance1 for its fully automated Idylla™ MSI Test. This 510(k) clearance reinforces Biocartis’ commitment to enable clinical molecular diagnostics in the U.S. Now,

    • GlobeNewswire

      Press release Biocartis Group NV: Biocartis Creates New Share Option Plan and Cancels Outstanding Pool under Existing Share Option Plans

      PRESS RELEASE - REGULATED INFORMATION 24 February 2023, 07:00 CET Biocartis Creates New Share Option Plan and Cancels Outstanding Pool under Existing Share Option Plans Mechelen, Belgium, 24 February 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that its board of directors created, within the framework of the authorized capital, 8.3 million share options (each share option having the form of a sub

    • GlobeNewswire

      Press release Biocartis Group NV: Biocartis announces 2022 results and 2023 outlook

      PRESS RELEASE - REGULATED INFORMATION23 February 2023, 07:00 CET BIOCARTIS ANNOUNCES 2022 RESULTS AND 2023 OUTLOOK The Company will host a conference call with live webcast presentation today at 14:30 CET / 13:30 GMT (UK) / 08:30 EST (US) to discuss the full year 2022 results Mechelen, Belgium, 23 February 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces its operational highlights and financial resul

    • GlobeNewswire

      Press release Biocartis Group NV: Biocartis announces change in Board composition

      PRESS RELEASE 22 February 2023, 07:00 CET BIOCARTIS ANNOUNCES CHANGE IN BOARD COMPOSITION Mechelen, Belgium, 22 February 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that Mr. Roald Borré has resigned as Director of the Company, and that upon the recommendation of the Company’s Remuneration and Nomination Committee, the Board of Directors has appointed Mr. Bryan Dechairo as new independent Board m

    • GlobeNewswire

      Press release Biocartis Group NV: Biocartis Announces 2022 Full Year Results on 23 February 2023

      PRESS RELEASE - REGULATED INFORMATION 16 February 2023, 07:00 CET BIOCARTIS ANNOUNCES 2022 FULL YEAR RESULTS ON 23 FEBRUARY 2023 Mechelen, Belgium, 16 February 2023 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces that it will report its 2022 full year results on 23 February 2023 at 07:00 CET. That day, the Biocartis management team will also host a conference call with live webcast presentation at 14:30 CET /

    • GlobeNewswire

      Press release Biocartis Group NV: Biocartis Announces the Launch of the First Assay Developed With the New Idylla™ Flex Technology

      PRESS RELEASE 9 February 2023, 07:00 CET BIOCARTIS ANNOUNCES THE LAUNCH OF THE FIRST ASSAY DEVELOPED WITH THE NEW IDYLLA™ FLEX TECHNOLOGY Mechelen, Belgium, 9 February 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the launch of the Idylla™ IDH1-2 Mutation Assay Kit (RUO)1 among selected customers. The assay is the first test developed with the new Idylla™ FLEX technology that separates the generic

    • GlobeNewswire

      Press release Biocartis Group NV: BIOCARTIS MEETS 2022 KEY OBJECTIVES

      PRESS RELEASE: REGULATED INFORMATION17 January 2023, 17:40 CET BIOCARTIS MEETS 2022 KEY OBJECTIVES Mechelen, Belgium, 17 January 2023 - Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces that the Company has achieved its 2022 key business objectives focused on three performance indicators: Idylla™ product revenues, gross margins on product sales and operating cash burn. Based on non-audited numbers for 2022, Biocar

    • GlobeNewswire

      Press release Biocartis Group NV: Completion of Comprehensive Recapitalization Transactions

      PRESS RELEASE: REGULATED INFORMATION16 January 2023, 17:40 CET Completion of Comprehensive Recapitalization Transactions Mechelen, Belgium, 16 January 2023 –Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART) is pleased to announce that the final steps in the previously announced comprehensive recapitalization transactions have been completed today. The initial holders of the Company's 4.50% new second lien secured convertible

    • GlobeNewswire

      Press release Biocartis Group NV: Disclosure of transparency notifications

      PRESS RELEASE: REGULATED INFORMATION 4 January 2023, 17:40 CET Disclosure of transparency notifications Mechelen, Belgium, 4 January 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down miscellaneous

    • GlobeNewswire

      Press release Biocartis Group NV: Completion of Mandatory Conversion

      PRESS RELEASE: REGULATED INFORMATION16 December 2022, 17:40 CET Completion of Mandatory Conversion Capitalized terms not otherwise defined in this notice shall have the meaning given to them in the Terms and Conditions of the Bonds. Mechelen, Belgium, 16 December 2022 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART) announces today that, in accordance with Condition 5(m) of the terms and conditions of the Company's 4.00%

    • GlobeNewswire

      Press release Biocartis Group NV: Mandatory Conversion Bondholder Notification

      PRESS RELEASE: REGULATED INFORMATION5 December 2022, 17:40 CET Mandatory Conversion Bondholder Notification Capitalised terms not otherwise defined in this notice shall have the meaning given to them in the Terms and Conditions of the Bonds. Mechelen, Belgium, 5 December 2022 – This announcement constitutes a notice (the “Mandatory Conversion Bondholder Notification”) in accordance with, respectively, Condition 5(m)(v) of the terms and conditions of the 4.00% convertible bonds due 2024/2027 (the

    • GlobeNewswire

      Press release Biocartis Group NV: Biocartis Announces Successful Rights Offering

      PRESS RELEASE: INSIDE INFORMATION / REGULATED INFORMATION29 November 2022, 15:15 CET Biocartis Announces Successful Rights Offering: Existing Shareholders and New Investors Fully Subscribed for the Rights Offering Following Successful Private Placement of the Scrips and Backstop Undertakings Mechelen, Belgium, 29 November 2022 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the successful closing of the

    • GlobeNewswire

      Press release Biocartis Group NV: Biocartis Announces 55.91% of Offered Shares Subscribed at Closing of Rights Subscription Period for Holders of Preferential Rights, and Start of Sale of Scrips through Private Placement to Inst. Investors

      PRESS RELEASE: INSIDE INFORMATION / REGULATED INFORMATION 29 November 2022, 10:30 CET Biocartis Announces 55.91% of Offered Shares Subscribed at Closing of the Rights Subscription Period for Holders of Preferential Rights, and Start of the Sale of the Scrips through a Private Placement to Institutional Investors Warning: An investment in the Company's ordinary shares (the "Shares", including the Offered Shares (as defined below) and the new Shares issuable upon conversion of the Existing Convert

    • GlobeNewswire

      Press release Biocartis Group NV: Expected Mandatory Conversion Bondholder Notification

      PRESS RELEASE: REGULATED INFORMATION 28 November 2022, 17:45 CET Expected Mandatory Conversion Bondholder Notification Capitalised terms not otherwise defined in this notice shall have the meaning given to them in the Terms and Conditions of the Bonds. Mechelen, Belgium, 28 November 2022 – This announcement constitutes a notice (the “Expected Mandatory Conversion Bondholder Notification”) in accordance with, respectively, Condition 5(m)(v) of the terms and conditions of the 4.00% convertible bon

    • GlobeNewswire

      Press release Biocartis Group NV: Biocartis launches a rights offering (with extra-legal preferential rights for existing shareholders) of a maximum of 33,476,932 offered shares, amounting to a maximum of EUR 25,107,699.00

      ADVERTISEMENT PRESS RELEASE: INSIDE INFORMATION / REGULATED INFORMATION 16 November 2022, 07:00 CET Biocartis launches a rights offering (with extra-legal preferential rights for existing shareholders) of a maximum of 33,476,932 offered shares, amounting to a maximum of EUR 25,107,699.00 Warning: An investment in the Company's ordinary shares (the "Shares", including the Offered Shares (as defined below) and the new Shares issuable upon conversion of the Existing Convertible Bonds, upon conversi